Skip to main content
The NCI Community Hub will be retiring in May 2024. For more information please visit the NCIHub Retirement Page:https://ncihub.cancer.gov/groups/ncihubshutdown/overview
close

NCL Method ITA-17

By Timothy Potter, Barry Neun, Jamie Rodriguez, Anna Ilinskaya, Marina Dobrovolskaia

In Vitro Induction of Leukocyte Procoagulant Activity by Nanoparticles

Listed in Datasets | publication by group NCL Protocols

Version 2.0b - published on 24 Jul 2020 doi:10.17917/ZQ6R-KD69 - cite this

Licensed under these terms

Description

Leukocyte procoagulant activity (PCA) is accepted as an important component in the onset of disseminated intravascular coagulation (DIC). DIC is common in acute promyelocytic leukemia (APL) and other forms of cancer[1-5]. DIC in cancer patients is often observed after initiation of therapy with cytotoxic oncology drugs that act by altering DNA replication (e.g., doxorubicin, daunorubicin, and vincristin) [3, 6]. Cytotoxic oncology drugs acting by other mechanisms, (e.g., methotrexate and paclitaxel) do not induce DIC [7-8]. DIC is also a common complication in sepsis [9-12]. Cytotoxic drugs (doxorubicin, vincrisitn, and daunorubicin) and endotoxin have previously been shown to induce leukocyte PCA in vitro and DIC in vivo [13-21]. In vitro, doxorubicin-induced leukocyte PCA has previously been linked to DIC in vivo [3].

Content List

Cite this work

Researchers should cite this work as follows:

Tags

Recommendations

Powered by ...

NCL Protocols

NCL Protocols group image

When watching a publication, you will be notified when a new version is released.